Graft versus host disease Pipeline constitutes 60+ key companies continuously working towards developing 60+ GVHD treatment therapies, analyses DelveInsight
DelveInsight’s “Graft versus host disease Pipeline Insight – 2023” report provides comprehensive global coverage of available, marketed, and pipeline GVHD therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Graft versus host disease pipeline domain.
Key Takeaways from the Graft versus host disease Pipeline Report
- DelveInsight’s Graft versus host disease pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Graft versus host disease treatment.
- Key Graft versus host disease companies such as Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others are evaluating new drugs for GVHD to improve the treatment landscape.
- Promising Graft versus host disease pipeline therapies in various stages of development include ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.
Request a sample and discover the recent advances in GVHD treatment drugs @ Graft versus host disease Pipeline Report
The Graft versus host disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Graft versus host disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the GVHD clinical trial landscape.
Graft versus host disease Overview
Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. “Graft” refers to transplanted, or donated tissue, and “host” refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT).
Find out more about Graft versus host disease treatment drugs @ Drugs for Graft versus host disease Treatment
A snapshot of the Graft versus host disease Pipeline Drugs mentioned in the report:
|
GvHD Drugs |
Company |
Phase |
MoA |
RoA |
|
Itolizumab |
Biocon |
Phase III |
CD6 antigen inhibitors |
Intravenous |
|
T-Guard |
Xenikos |
Phase III |
T lymphocyte inhibitors; Protein synthesis inhibitors |
Intravenous |
|
MaaT013 |
MaaT Pharma |
Phase III |
Bacteria replacements; Gastrointestinal microbiome modulators |
Rectal |
|
Axatilimab |
Syndax Pharmaceuticals |
Phase II |
Macrophage colony stimulating factor receptor antagonists |
Intravenous |
|
TQ 05105 |
Chia Tai Tianqing Pharmaceutical Group |
Phase I/II |
Janus kinase-2 inhibitors |
Oral |
Learn more about the emerging Graft versus host disease pipeline therapies @ Graft versus host disease Clinical Trials
Graft versus host disease Therapeutics Assessment
The Graft versus host disease pipeline report proffers an integral view of GVHD emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Graft versus host disease Pipeline Report
- Coverage: Global
- GVHD Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- GVHD Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Graft versus host disease Therapeutics Assessment By Route of Administration: Intravenous, Oral, Rectal.
- Key GVHD Companies: Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others
- Key GVHD Pipeline Therapies: ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.
Dive deep into rich insights for new drugs for GVHD treatment; visit @ Graft versus host disease Medications
Table of Contents
- Introduction
- Executive Summary
- Graft versus host disease (GVHD): Overview
- What is Graft versus host disease (GVHD)?
- Types of Graft versus host disease (GVHD)
- Causes
- Epidemiology and Risk Factors
- Disease Management
- GVHD Pipeline Therapeutics
- Comparative Analysis
- Graft versus host disease Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Graft versus host disease (GVHD)– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- Itolizumab: Biocon
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ASC930: ASC Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- TQ 05105: Chia Tai Tianqing Pharmaceutical Group
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Graft versus host disease (GVHD) Key Companies
- Graft versus host disease (GVHD) Key Products
- Graft versus host disease (GVHD) Unmet Needs
- Graft versus host disease (GVHD) Market Drivers and Barriers
- Graft versus host disease (GVHD) Future Perspectives and Conclusion
- Graft versus host disease (GVHD) Analyst Views
- Appendix
About DelveInsight
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services